Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile August 10, 2026 Trial met its primary endpoint, with a significantly higher proportion of clinical responders on divesiran (88%) compared to placebo (19%); placebo-adjusted response rate = 69% Both divesiran dose groups showed substantial primary endpoint efficacy; 93.8% response rate at Q6W and 81.3% response rate at Q12W Divesiran was observed to be well tolerated with no new safety findings Phase 3 PV trial evaluating divesiran Q12W vs. placebo anticipated to initiate in 1H’27 Investor conference call and webcast to be held today, August 10, 2026 at 8:00 a.m. ET
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results August 10, 2026 Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second quarter ended June 30, 2026. Business Highlights Divesiran: First-in-class siRNA silencing TMPRSS6 for polycythemia vera (PV) and other blood disorders Presented follow-up data from the Phase 1 SANRECO trial [...]
‘Good growth in every postcode’ is a woeful catchphrase August 10, 2026 Burnham and co's bid to 'back British' and generate 'good growth' everywhere is a bid to fool voters with their own money, writes Eliot Wilson.
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera August 9, 2026 Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced a conference call and webcast to discuss topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera (PV) scheduled for tomorrow, Monday, August 10, 2026 at 8:00 a.m. EDT. Investor Webcast & Conference Call [...]
Stop burying us in swollen corporate reports, says audit watchdog boss August 9, 2026 The boss of the audit watchdog has warned that the size of annual reports has swelled out of control, costing directors too much time. Richard Moriarty, chief executive of the Financial Reporting Council, said the costs and expectations surrounding annual reports have steadily ballooned as more companies devote pages to environmental, social and governance issues [...]
Battery Ventures Promotes Brandon Gleklen to Partner August 7, 2026 Gleklen, who invests in AI-application companies, joins new principal Jason Mendel and eight other investors globally promoted to new roles
Algoma Central Corporation Reports Financial Results for the 2026 Second Quarter August 7, 2026 Strategic acquisitions, expanded credit facilities, and strong segment performance position Algoma for continued growth.
As it happened: Stocks rise despite new tensions in Strait of Hormuz; Oil price climbs August 7, 2026 Welcome back to the City AM liveblog. New tensions in the Strait of Hormuz this morning are leaving markets on edge and handing a blow to earlier optimism around a peace deal between the US and Iran. Oil is moving higher, reversing some of the drawback from the beginning of this week, after an attack [...]
Allianz Delivers Record Result and Is Well on Track to Achieve Its Targets August 7, 2026 2Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806509750/en/ Total business volume at 45.6 billion euros, an internal growth of 5.7 percent1, with contributions from all segments. Asset Management delivers excellent growth. Operating profit rises 10.6 percent to a record level of 4.9 billion euros. Shareholders’ core net income at 2.6 [...]
Prothena Reports Second Quarter 2026 Financial Results and Business Highlights August 6, 2026 Net cash used in operating and investing activities was $25.7 million in the second quarter and net cash provided by operating and investing activities was $3.2 million for the first six months of 2026; quarter-end cash and restricted cash position was $289.1 million Guidance updated to include shares repurchased through July 30, 2026 and now expects to end the year with approximately $259 million (midpoint) in cash, cash equivalents and restricted cash Results from partner Roche evaluating prasinezumab in patients with early Parkinson’s disease from the Phase 2b PADOVA clinical trial published in The Lancet Multiple research collaborations with industry partners ongoing to explore the potential of our CYTOPE® technology over the next 12 to 24 months